FDA and HCV-TARGET team up to help doctors and patients optimize hepatitis C therapy

HCV-TARGET Map
The Hepatitis C Therapeutic Registry and Research Network

As doctors prepare to manage an influx of new hepatitis C patients and treatment options, a collaboration among academia, industry and the U.S. Food and Drug Administration is poised to deliver real-world data that can help doctors and patients optimize their treatment experience.

Co-led by Dr. David R. Nelson at the University of Florida and Dr. Michael W. Fried at the University of North Carolina at Chapel Hill, the Hepatitis C Therapeutic Registry and Research Network joined forces with the FDA to share national data on how newly approved hepatitis C therapeutics are used and managed in routine practice.

HCV-TARGET is rooted in the infrastructure and collaborative network of the national Clinical and Translational Science Award (CTSA) consortium. It is sponsored in part by multiple pharmaceutical companies.

Read more:
FDA, academia and industry team up to end hepatitis C

Related Resources & News